共查询到20条相似文献,搜索用时 203 毫秒
1.
2.
目的 构建可视化预测肺腺癌(LUAD)脑转移风险概率的列线图模型,提高患者生存率。方法 研究纳入监测、流行病学和最终结果(SEER)数据库中58 928例LUAD患者,并按7∶3比例随机分为训练集和验证集。在训练集中采用Lasso回归与多因素Logistic回归分析筛选最有意义的预测变量,构建预测LUAD脑转移的列线图模型。采用受试者工作特征(ROC)曲线的曲线下面积(AUC),Boostrap绘制校正曲线,Brier评分验证模型区分度及校准度,决策曲线分析(DCA)评价预测模型的临床效能。结果 最终筛选出7个独立影响因素构建列线图预测模型。训练集和验证集列线图预测LUAD患者发生脑转移概率的AUC分别为0.853(95%CI:0.849~0.858)和0.851(95%CI:0.844~0.857),校准曲线显示模型预测概率与实际观察概率具有较高的一致性,Brier评分均为0.092,DCA显示净收益率较高,模型临床效能较好。结论 本研究成功建立了预测LUAD脑转移的列线图模型,该模型能够准确区分脑转移高风险患者,可以有效指导临床医师制订个体化治疗方案。 相似文献
3.
4.
摘 要:[目的] 探讨泛凋亡(PANoptosis)对肺腺癌(lung adenocarcinoma,LUAD)患者预后及免疫微环境的预测价值。[方法] 从TCGA数据库下载LUAD样本与正常样本的基因表达谱及临床数据,从已发表的文献中获取PANoptosis相关基因并分析其在肿瘤组和对照组间的差异表达基因。通过单变量Cox分析和LASSO-Cox回归分析构建生存预后模型,将患者按风险评分划为高、低风险组。通过Kaplan-Meier生存曲线和受试者工作特征(receiver operating characteristic,ROC)曲线下面积(area under the curve,AUC)评价模型的预测性能,再对模型风险评分进行独立预后分析。GO和KEGG富集分析探索生物功能和潜在的信号通路。采用TIMER数据库ESTIMATE算法综合分析PANoptosis相关基因与免疫微环境相关性。通过qRT-PCR验证PANoptosis预后相关基因在LUAD组织和正常肺组织间的差异表达。[结果] 共有15个PANoptosis相关基因在LUAD组和正常组间存在差异性表达,从中筛选出4个PANoptosis预后相关基因(RIPK3、NLRP3、FADD、MLKL)。在LASSO-Cox回归模型中,高风险组的生存率低于低风险组(P<0.001)。单变量和多变量Cox分析显示该评分模型是LUAD的独立预后因素(HR=2.179,95%CI:1.347~3.524,P=0.001),而GO和KEGG分析显示差异表达基因主要富集于与免疫相关的通路。高低风险组之间免疫微环境、免疫细胞差异和免疫检查点基因表达差异显著。此外,qRT-PCR实验也证实PANoptosis相关基因FADD(P=0.007)和NLRP3(P<0.001)在LUAD组和正常组之间表达存在差异。[结论] 本研究构建的PANoptosis相关基因的生存预后模型可以预测LUAD患者的预后及免疫微环境。 相似文献
5.
目的:探索TXNs家族与肺腺癌(LUAD)预后的相关性并建立预后预测模型。方法:利用癌症基因组图谱(TCGA)数据,采用Cox单因素及多因素分析筛选TXNs家族中LUAD的独立预后因素,计算基于TXNs家族的风险评分RS,并分析RS与临床病理学参数的关系,最终构建包含RS的预后预测列线图模型。结果:TMX4是独立预后保护因素,TXNRD1是独立预后危险因素;基于TMX4与TXNRD1的风险评分RS高危患者预后差(P=0.005),且与较晚的T分期呈正相关(P<0.05);利用独立预后因素RS、T分期、年龄构建的列线图能够直观个体化地预测LUAD患者的预后。结论:基于TXNs家族构建的LUAD预后预测列线图模型有望成为LUAD预后判断的有效指标。 相似文献
6.
7.
8.
9.
摘 要:[目的] 联合免疫相关长链非编码RNA(long non-coding RNA,lncRNA),探索用于评估结肠癌预后的新模型。[方法] 我们从癌症基因图谱(the cancer genome atlas,TCGA)数据库中下载结肠癌患者的临床数据和基因表达信息,从分子标记数据库v4.0获得免疫相关的基因。Perl 软件和 R软件用于数据处理和分析。利用R语言的相关性检验获得结肠癌免疫相关lncRNAs。结合临床数据,利用单因素Cox回归分析筛选出与结肠癌预后相关的免疫相关lncRNAs,随后进一步多因素分析,筛选出构建风险评分模型的lncRNAs。根据风险评分的中位数将患者分为高风险组和低风险组,运用 Kaplan-Meier(K-M)生存分析及独立预后因素评估对模型进行评价,并将此模型联合其他临床因素构建列线图,对个体进行生存率预测。[结果] 单因素Cox回归分析筛选出33个与结肠癌预后相关的免疫相关lncRNA,多因素Cox回归分析最终确定12个免疫相关lncRNA用来构建风险评分模型。以中位风险评分作为临界值,患者可被分为高风险组和低风险组,低风险和高风险组的5年生存率分别为86.1%和42.7%。此外,风险评分模型可作为结肠癌的独立预后因子,联合结肠癌其他临床因素和风险评分,建立了列线图以预测结肠癌个体生存率,该列线图的C指数为0.807(95%CI:0.762~0.854),校准图显示预测值与实际观测值一致性较好。[结论] 由12个免疫相关lncRNA构成的风险评分模型可用于评估结肠癌预后,并根据构建的列线图可预测结肠癌患者的生存率。 相似文献
10.
11.
目的:探究肺腺癌中与免疫治疗相关氧化应激基因(IROSG)及其与肿瘤组织免疫浸润和患者预后的关系。方法:从TCGA数据库和GEO数据库下载肺腺癌患者IROSG表达数据及相关临床信息。对非小细胞肺癌免疫治疗队列进行差异基因表达分析以获取免疫治疗相关基因,然后与从GeneCards数据库筛选的氧化应激相关基因取交集得到IROSG。基于得到的IROSG对肺腺癌患者进行分型,对亚型的差异表达基因进行单因素COX、LASSO和多因素COX回归分析以构建预后模型。使用模型公式计算每个患者的风险评分,并将患者划分为高、低风险组。从多个层面验证模型的预测效能,并进行肿瘤微环境(TME)分析、免疫治疗反应预测和药物敏感性分析。结果:通过数据库分析获取82个IROSG,IROSG高表达的肺腺癌患者预后较好(P<0.05)。基于IROSG表达水平分型和风险评分构建的肺腺癌患者预后模型预测能力好,基于风险评分和病例特征等预后因子构建的列线图和校正曲线能较好地预测肺腺癌患者的总生存率。低风险组主要富集于同种异体移植物排斥和自身免疫性疾病等通路,而高风险组主要富集在细胞周期和DNA复制等通路上,且低风险组肺... 相似文献
12.
13.
14.
目的探讨研究转移性结直肠癌患者的生存率和预后风险因素,构建预后风险预测评分并进行验证。方法选取2010年至2015年美国监测、流行病和结果队列(surveillance,epidemiology,and end results,SEER)诊断的转移性结直肠癌患者。采用Kaplan-Meier法研究患者生存率,并采用多因素Cox回归分析研究影响患者预后的风险因素。基于上述因素构建预后风险预测评分并进行预测准确性的内部评价,同时采用2016年诊断的患者进行预测评分的外部验证。结果研究共选取转移性结直肠癌患者37 092例,5年生存率为10.6%。年龄较高、黑种人、组织学分化程度较低、T分期较高、N分期、高癌胚抗原水平以及骨、脑、肝和肺转移是死亡的风险因素,而女性、已婚状态、有保险、非右半结肠和原发部位手术是死亡的保护性因素。验证性结果显示该预测评分具有较高的内部稳定性和外部适应性。结论转移性结直肠癌患者预后较差,基于预后风险因素建立的预测模型能准确预测患者生存概率,帮助医生制定个体化治疗方案,提高患者生存率。 相似文献
15.
Kai Lei Binghua Tan Ruihao Liang Yingcheng Lyu Kexi Wang Wenjian Wang Kefeng Wang Xueting Hu Duoguang Wu Huayue Lin Minghui Wang 《American journal of cancer research》2022,12(11):5160
Necroptosis is a new programmed formation of necrotizing cell death, which plays important role in tumor biological regulation, including tumorigenesis and immunity. In this study, we aimed to establish and validate a prediction model based on necroptosis-related genes (NRGs) for lung adenocarcinoma (LUAD) prognosis and tumor immunity. The training set consisted of samples from The Cancer Genome Atlas (TCGA) dataset (n = 334), and the validation sets consisted of samples from the Gene Expression Omnibus (GEO) (n = 439) and clinical (n = 20) datasets. Gene Oncology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis showed that 28 necroptosis-related differentially expressed genes (DEGs) were enriched in cell death and immune regulation. RT-qPCR and western blot results showed the low expression of necroptosis markers in LUAD cells. A prognostic gene signature based on 6 NRGs (PYGB, IL1A, IFNAR2, BIRC3, H2AFY2, and H2AFX) was constructed and the risk score was calculated. Multivariate Cox regression analysis showed that the risk score was an independent risk factor [hazard ratio (HR) = 1.220, 95% confidence interval (CI): 1.154-1.290, P<0.001]. In the TCGA cohort, a high-risk score was associated with poor prognosis, weak immune infiltration, and low expression at immune checkpoints, which was validated in the GEO and clinical cohorts. Our findings showed that the patients in the low-risk group had a better progression-free survival (PFS) [not reached vs. 8.5 months, HR = 0.18, 95% CI: 0.04-0.72, P<0.001] than those in the high-risk score group. Immunotherapy tolerance was found to be correlated with the high-risk score, and the risk score combined with PD-L1 (AUC = 0.808, 95% CI: 0.613-1.000) could better predict the immunotherapy response of LUAD. A nomogram was shown to have a strong ability to predict the individual survival rate of patients with LUAD in the TCGA and cohorts. We constructed and validated a potential prognostic signature consisting of 6 NRGs to predict the prognosis and tumor immunity of LUAD, which may be helpful to guide the individualized immunotherapy of LUAD. GSE68465相似文献
16.
17.
Jian Zhang Yan Li Yue Yang Jian Huang Yue Sun Xi Zhang Xianglong Kong 《Cancer science》2024,115(1):109-124
Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Most patients are diagnosed at an advanced stage, therefore it is crucial to identify novel prognostic biomarkers for LUAD. As important regulatory cells, inducible regulatory T cells (iTregs) play a vital role in immune suppression and are important for the maintenance of immune homeostasis. This study explored the prognostic value and therapeutic effects of iTreg-related genes in LUAD. Data for LUAD patients, including immune infiltration data, RNA sequencing data, and clinical features, were acquired from The Cancer Genome Atlas, Gene Expression Omnibus, and Tumor Immune Single-cell Hub 2 databases. Immune-related subgroups with different infiltration patterns and iTreg-related genes were identified through univariate and multivariate Cox regression analyses and weighted correlation network analysis. Functional enrichment analyses were performed to explore the underlying mechanisms of iTreg-related genes. A prognostic risk signature was constructed using Cox regression analysis with the least absolute shrinkage and selection operator penalty. The ESTIMATE algorithm was applied to determine the immune status of LUAD patients. We applied the constructed signature to predict chemosensitivity and performed single-cell RNA sequencing analysis. The infiltration of iTregs was identified as an independent factor for predicting patient outcomes. We constructed a prognostic signature based on seven iTreg-related genes (GIMAP5, SLA, MS4A7, ZNF366, POU2AF1, MRPL12, and COL5A1), which was applied to subdivide patients into high- and low-risk subgroups. Our results revealed that patients in the iTreg-related low-risk subgroup had a better prognosis and possibly greater sensitivity to traditional chemotherapy. Our study provides a novel iTreg-related signature to elucidate the mechanisms underlying LUAD prognosis and promote individualized chemotherapy treatment. 相似文献
18.
目的:探索嘌呤能受体X1(purinergic receptor,P2RX1)与肺腺癌(LUAD)患者预后及免疫细胞浸润的相关性。方法:利用生物信息学技术分析非小细胞肺癌中P2RX1的表达及其甲基化与患者预后的关系,对P2RX1共表达基因进行富集分析并筛选核心基因。利用TIMER 2.0数据库、R软件等分析P2RX1与免疫细胞、免疫检查点、免疫基质评分等的相关性。结果:P2RX1在LUAD中表达下调,低表达P2RX1的患者预后较差(P<0.05),且P2RX1与肿瘤纯度、分期等临床病理因素有关(P<0.05)。P2RX1的表达与肺鳞癌患者预后无明显相关。Cg06475633等P2RX1 CpG位点甲基化与患者预后相关。P2RX1共表达基因主要富集于免疫细胞活化、分化等通路和生物学进程,核心基因主要包括BTK、IKZF1等。P2RX1的表达与B细胞浸润、免疫/基质评分、PD-1、CTLA-4等多个免疫检查点显著相关(P<0.05)。结论:P2RX1有望成为LUAD诊断和免疫治疗的新靶点。 相似文献
19.
Background and Aim: Hundreds of consistently altered metabolic genes have been identified in breast cancer
(BC), but their prognostic value remains to be explored. Therefore, we aimed to build a prediction model based
on metabolism-related genes (MRGs) to guide BC prognosis. Methods: Current work focuses on constructing a
novel MRGs signature to predict the prognosis of BC patients using MRGs derived from the Virtual Metabolic
Human (VMH) database, and expression profiles and clinicopathological data from The Cancer Genome Atlas
(TCGA) and Gene Expression Omnibus (GEO) databases. Results: The 3-MRGs-signature constructed by SERPINA1, QPRT and PXDNL was found to be an independent prognostic factor for the survival of patients, and
based on the model, the overall survival (OS) of the high-risk group was significantly lower. Furthermore, a
nomogram was developed based on risk score and independent prognostic clinical indicators, and its validity
of survival prediction was confirmed by the calibration curve, the concordance index, decision curve analysis
and receiver operating characteristic curve. The ssGSEA analysis showed a negative correlation between immune
cell infiltration and risk score, which is consistent with the GSEA result showing that low-risk score group was
associated with activated immune processes. Half-maximal inhibitory concentration of chemotherapeutic drugs
was estimated by pRRophetic algorithm to guide clinical medication. Conclusion: We constructed and validated
an effective 3-MRGs (SERPINA1, QPRT and PXDNL)-based prognostic model, and demonstrated that lower-risk
patients were associated with higher immune infiltrations, underscoring the importance of immune ecosystems in
determining the prognosis of BC patients. 相似文献
20.